A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer
Public ClinicalTrials.gov record NCT04752332. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after surgery. Participants must have breast cancer that is hormone receptor positive (HR+) and human epidermal receptor 2 positive (HER2+). Your participation could last up to 10 years depending on how you and your tumor respond.
Study identification
- NCT ID
- NCT04752332
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 10, 2021 (Actual)
- Primary completion
- Jun 26, 2024 (Actual)
- Completion
- Jun 26, 2024 (Actual)
- Last update posted
- Jul 15, 2025
2021 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Palo Verde Cancer Specialists | Glendale | Arizona | 85304 | — |
| TRIO-US (Translational Research in Oncology-US) | Los Angeles | California | 90024 | — |
| Millennium Oncology - Hollywood | Hollywood | Florida | 33024 | — |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33705 | — |
| Mt. Sinai Hospital PRiSMS | Chicago | Illinois | 60608 | — |
| Cornell-Beshore Cancer Institute | Joplin | Missouri | 64804 | — |
| The Valley Hospital | Ridgewood | New Jersey | 07450 | — |
| Sarah Cannon Research Institute SCRI | Nashville | Tennessee | 37203 | — |
| Texas Oncology - Medical City Dallas | Dallas | Texas | 75230 | — |
| Northwest Cancer Specialists PC | The Woodlands | Texas | 77380 | — |
| Texas Oncology - Medical City Dallas | The Woodlands | Texas | 77380 | — |
| US Oncology | The Woodlands | Texas | 77380 | — |
| USO-Southern Cancer Center, P.C. | The Woodlands | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04752332, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2025 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04752332 live on ClinicalTrials.gov.